The Role of Angiogenesis Inhibitors in Cancer Treatment

Register to Attend Online (Free)

You'll be able to join live while we record.
You are all registered!

You will get an email with all the information you'll need to connect.

We look forward to seeing you!
Oops! Something went wrong while submitting the form.

Navigating the intricate world of angiogenesis and its inhibitors offers a glimpse into the marvels and mysteries of the human body and the potential of modern medicine. One defining characteristic of tumors are their ability to hijack the process of angiogenesis.

Understanding Angiogenesis

What is Angiogenesis?

Angiogenesis, in simple terms, is the process by which new blood vessels form from pre-existing ones. Think of it as the construction crew of our body, building roads (or blood vessels) to transport essential nutrients and oxygen to different parts of the body.

Importance of Angiogenesis

Just as roads are crucial for transporting goods to different parts of a city, angiogenesis is vital for our body's growth, repair, and overall health. Without angiogenesis, wounds wouldn't heal, and organs wouldn't get the nutrients they need. Sounds essential, right?

A Brief History of Angiogenesis Discovery

The Early Days of Angiogenesis

The concept of angiogenesis was introduced in the early 20th century. However, its significance in the realm of medicine became more pronounced in the 1970s when Dr. Judah Folkman proposed that tumors require angiogenesis to grow, and inhibiting this could potentially halt tumor growth.

The Advent of Angiogenesis Inhibitors

Inspired by Folkman's hypothesis, the subsequent decades witnessed intensified research efforts, culminating in the discovery of angiogenesis inhibitors by the late 20th century.

Clinical Trials and Approvals

The 1990s saw the first angiogenesis inhibitors being tested in clinical trials. By the early 2000s, drugs like Bevacizumab (Avastin) were approved, offering a new ray of hope for many cancer patients.

The Link Between Angiogenesis and Cancer

Tumor Growth and Angiogenesis

While angiogenesis is crucial for our body's normal functions, it can also play a role in cancer growth. Imagine a city where roads are built to support rogue neighborhoods. Similarly, tumors can hijack the angiogenesis process to feed themselves and grow.

Tumor Exploitation of Angiogenesis

Tumors are adept at survival. They release signals that trick the body into creating new blood vessels. These vessels then supply the tumor with the nutrients and oxygen it needs to grow and spread, much like a thief diverting a water supply to their hideout.

Delving into Angiogenesis Inhibitors

Mechanism of Action

Angiogenesis inhibitors function by blocking the signals tumors release to form new blood vessels, effectively starving the tumor of its essential supplies.

Types: Small Molecules vs. Monoclonal Antibodies

  • Small Molecules: These are low-weight compounds that can penetrate cells, disrupting the internal pathways that promote angiogenesis.
  • Monoclonal Antibodies: These proteins are designed to target and bind to specific proteins on the cell surface, preventing them from initiating angiogenesis.

Delivery Methods

Angiogenesis inhibitors can be delivered in various ways:

  • Intravenous Infusion: Directly into the bloodstream.
  • Oral Tablets: Taken by mouth and absorbed in the digestive system.
  • Topical Creams: Applied on the skin, especially for certain skin cancers.

Ongoing Research and Future Prospects

Research into angiogenesis inhibitors is a dynamic field. Scientists are continually exploring newer inhibitors that are more effective and come with fewer side effects.

Application in Cancer Treatment

Cancers Treated with Angiogenesis Inhibitors

These inhibitors have shown efficacy in treating cancers like colorectal, lung, kidney, and brain. However, they might be less effective for pancreatic or certain breast cancers.

Combination with Other Treatments

There's growing interest in combining angiogenesis inhibitors with other treatments, such as immunotherapy. This combination aims to enhance the overall effectiveness and improve patient outcomes.

Potential Side Effects and Considerations

Common and Rare Side Effects

Patients might experience side effects like high blood pressure, fatigue, and bleeding. More severe side effects, though rarer, include heart complications and wound healing issues.

Determining Candidacy for Angiogenesis Inhibitors

Oncologists consider the type and stage of cancer, the patient's overall health, and the tumor's reliance on angiogenesis to determine if angiogenesis inhibitors are suitable.


The exploration of angiogenesis and its inhibitors in cancer treatment has been a journey of hope, discovery, and continuous learning. As we look to the future, the potential of these inhibitors, especially in combination with other treatments, promises even better outcomes for cancer patients.


  1. How did the concept of angiogenesis inhibitors come about?
    Dr. Judah Folkman's 1970s hypothesis about inhibiting angiogenesis to starve tumors led to their discovery.
  2. What's the difference between small molecules and monoclonal antibodies?
    Small molecules disrupt internal cell pathways, while monoclonal antibodies target specific cell surface proteins.
  3. How are angiogenesis inhibitors administered?
    They can be given through intravenous infusion, oral tablets, or topical creams.
  4. Can angiogenesis inhibitors be combined with other treatments?
    Yes, there's growing interest in combining them with treatments like immunotherapy.
  5. How does an oncologist decide if a patient should receive these inhibitors?
    They assess the cancer type, stage, patient's health, and the tumor's reliance on angiogenesis.